Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
For Startups
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Adjuvia Therapeutics/

Library

Adjuvia Therapeutics

Biotech developing oral BBB-penetrant nanoparticle therapies for mitochondrial disease.

: 7
: Private company
: 2023
: San Francisco, CA, USUnited States

Adjuvia Therapeutics Website, Blog & Press Pages - aVenture Research

Library

adjuvia.comCrawled Oct 15, 2026

Topics

Publication type

Search the library

Content origin

Row density

Team

1 page

Team/team
The page introduces the scientists and leaders building Adjuvia Therapeutics' BBB-penetrant nanoparticle platform.

Contact

1 page

Contact/contact
Adjuvia Therapeutics accepts partnership, investment, and general inquiries.

Homepage

1 page

Homepage/
Adjuvia Therapeutics develops orally delivered, BBB-penetrant nanoparticle therapies that carry nature's most potent antioxidants into the brain, CNS, and organs to treat chronic and rare degenerative diseases.

Coverage

5 items

Venture Capital and Startup Funding Roundup, July 29, 2026techstartups.com/2026/07/29/venture-capital-startup-funding-roundup-july-29-2026-more/
San Francisco-based Adjuvia Therapeutics raises $8 million to move a mitochondrial disease therapy into the clinic, according to the July 29, 2026 funding roundup.
Jul 2026TechStartupsNews article
Adjuvia Therapeutics Closes $8 Million Series Seed Financing to Advance Novel Mitochondrial Disease Therapy into the Clinicventurebeat.com/business/adjuvia-therapeutics-closes-8-million-series-seed-financing-to-advance-novel-mitochondrial-disease-therapy-into-the-clinic
Adjuvia Therapeutics closes an $8 million Series Seed financing to advance its novel mitochondrial disease therapy into the clinic. JLO Ventures leads the round, with participation from Portfolia Ventures and biopharmaceutical industry leaders.
Jul 2026VentureBeatNews article
Adjuvia raises USD 8m to advance mitochondrial disease therapy into clinicallsci.com/news/venture-financing/adjuvia-raises-usd-8m-for-preclinical-stage-mitochondrial-therapy/
Adjuvia Therapeutics secures USD 8 million in Series Seed funding to advance ATI-105, its mitochondrial disease therapy, into Phase I trials.
Jul 2026AllSciNews article
Adjuvia Therapeutics Raises $8 Million Seed Round to Advance ATI-105 into Clinical Trialscitybiz.co/article/881165/adjuvia-therapeutics-raises-8-million-seed-round-to-advance-ati-105-into-clinical-trials/
Adjuvia Therapeutics raises an $8 million seed round to advance ATI-105 toward clinical testing. JLO Ventures leads the financing, with Portfolia Ventures participating; proceeds will support an IND submission and Phase 1 studies in mitochondrial disease.
Jul 2026citybizNews article